CAPTRUST Financial Advisors
OCUL icon

CAPTRUST Financial Advisors’s Ocular Therapeutix OCUL Stock Holding History

CAPTRUST Financial Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,500
Closed -$48K – 2147
2022
Q3 		$48K Buy
11,500
+1,000
+10% +$5.04K ﹤0.01% 1987
2022
Q2 		$42K Buy
10,500
+10,000
+2,000% +$37.8K ﹤0.01% 2885
2022
Q1 		$2K Hold
500
– – ﹤0.01% 4516
2021
Q4 		$3K Hold
500
– – ﹤0.01% 4293
2021
Q3 		$5K Hold
500
– – ﹤0.01% 3949
2021
Q2 		$7K Hold
500
– – ﹤0.01% 3714
2021
Q1 		$8K Hold
500
– – ﹤0.01% 3548
2020
Q4 		$10K Hold
500
– – ﹤0.01% 2573
2020
Q3 		$4K Hold
500
– – ﹤0.01% 2598
2020
Q2 		$4K Buy
+500
New +$3.31K ﹤0.01% 2454

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CAPTRUST Financial Advisors's OCUL Position: Q4 2022 in Review

CAPTRUST Financial Advisors sold out of Ocular Therapeutix (OCUL) in Q4 2022, closing a stake of 11,500 shares — an estimated $48K sold.

CAPTRUST Financial Advisors first reported a position in OCUL in Q2 2020 and held it in 10 quarters. The position peaked at $48K in Q3 2022. 116 funds tracked by Wall St. Rank hold OCUL as of Q4 2022.

  • CAPTRUST Financial Advisors reported no remaining Ocular Therapeutix position as of Q4 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 11,500 Ocular Therapeutix shares in Q4 2022, an estimated $48K.
  • CAPTRUST Financial Advisors first reported a position in Ocular Therapeutix in Q2 2020 and held it in 10 quarters.
  • CAPTRUST Financial Advisors's Ocular Therapeutix position peaked at $48K in Q3 2022.
  • 116 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2022, filed 15 Feb 2023.